SOPHIA ANTIPOLIS, FRANCE--(Marketwire - November 28, 2011) -
PRESS RELEASE
NicOx: Patient recruitment completed by Bausch + Lomb in glaucoma study
www.nicox.com
NicOx S.A. (NYSE Euronext Paris: COX) today announced that the ongoing
phase 2b
study of BOL-303259-X, conducted by its partner Bausch + Lomb, has
finished
recruitment. Bausch + Lomb anticipates that the study will be completed
by the
end of December 2011, with preliminary results expected in the first
quarter of
2012.
BOL-303259- is an NO-donating prostaglandin F2-alpha analog which is
thought to
lower intraocular pressure (IOP) through a dual mechanism of action. The
ongoing
study is intended to identify the most effective dose of BOL-
303259-X,
administered in the evening to patients with open-angle glaucoma or
ocular
hypertension, for the reduction of IOP.
About NicOx
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused
on the research, development and future commercialization of drug
candidates.
NicOx is applying its proprietary nitric oxide-donating R&D platform to
develop
an internal portfolio of New Molecular Entities (NMEs) for the
potential
treatment of inflammatory, cardio-metabolic and ophthalmological diseases.
The Company's pipeline includes several nitric oxide-donating NMEs, which
are in
development internally and with partners, who include Merck (known
as MSD
outside the United States and Canada), Bausch + Lomb, and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext
Paris
(Compartment B: Mid Caps).
This press release contains certain forward-looking statements.
Although the
Company believes its expectations are based on reasonable assumptions,
these
forward-looking statements are subject to numerous risks and
uncertainties,
which could cause actual results to differ materially from those
anticipated in
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
business are
presented in the 4(th) chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2010 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 25, 2011 and available on NicOx's
website
(www.nicox.com) and on the AMF's website (www.amf-france.org).
NICOX: Patient recruitment completed by Bausch + Lomb in glaucoma study:
http://hugin.info/143509/R/1566780/486563.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
[HUG#1566780]
